|
1
|
Okamoto R and Watanabe M: Role of
epithelial cells in the pathogenesis and treatment of inflammatory
bowel disease. J Gastroenterol. 51:11–21. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Matsuoka K and Hibi T: Treatment
guidelines in inflammatory bowel disease: the Japanese
perspectives. Dig Dis. 31:363–367. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ogata H, Matsui T, Nakamura M, Iida M,
Takazoe M, Suzuki Y and Hibi T: A randomised dose finding study of
oral tacrolimus (FK506) therapy in refractory ulcerative colitis.
Gut. 55:1255–1262. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lichtiger S, Present DH, Kornbluth A,
Gelernt I, Bauer J, Galler G, Michelassi F and Hanauer S:
Cyclosporine in severe ulcerative colitis refractory to steroid
therapy. N Eng J Med. 330:1841–1845. 1994. View Article : Google Scholar
|
|
5
|
Dignass A, Van Assche G, Lindsay JO,
Lémann MJ, Colombel JF, Danese S, D'Hoore A, Gassull M, Gomollón F,
et al: European Crohn's and Colitis Organisation (ECCO): The second
European evidence-based Consensus on the diagnosis and management
of Crohn's disease: Current management. J Crohns Colitis. 4:28–62.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chang KH, Burke JP and Coffey JC:
Infliximab versus cyclosporine As rescue therapy in acute severe
steroid-refractory ulcerative colitis: A systematic review and
meta-analysis. Int J Colorectal Dis. 28:287–293. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Laharie D, Bourreille A, Branche J, Allez
M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Nachury M, Moreau J,
et al: Ciclosporin versus infliximab in patients with severe
ulcerative colitis refractory to intravenous steroids: A parallel,
open-label randomised controlled trial. Lancet. 380:1909–1915.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hamilton MJ, Snapper SB and Blumberg RS:
Update on biologic pathways in inflammatory bowel disease and their
therapeutic relevance. J Gastroenterol. 47:1–8. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kornbluth A and Sachar DB: Practice
Parameters Committee of the American College of Gastroenterology:
Ulcerative colitis practice guidelines in adults: American College
Of Gastroenterology, Practice Parameters Committee. Am J
Gastroenterol. 105:501–523. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sjöberg M, Walch A, Meshkat M, Gustavsson
A, Järnerot G, Vogelsang H, Hertervig E, Novacek G, Friis-Liby I,
Blomquist L, et al: Infliximab or cyclosporine As rescue therapy in
hospitalized patients with steroid-refractory ulcerative colitis: A
retrospective observational study. Inflamm Bowel Dis. 18:212–218.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dean KE, Hikaka J, Huakau JT and Walmsley
RS: Infliximab or cyclosporine for acute severe ulcerative colitis:
A retrospective analysis. J Gastroenterol Hepato. 27:487–492. 2012.
View Article : Google Scholar
|
|
12
|
Nakase H, Matsumura K, Yoshino T and Chiba
T: Systematic review: Cytomegalovirus infection in inflammatory
bowel disease. J Gastroenterol. 43:735–740. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Criscuoli V, Mocciaro F, Orlando A,
Rizzuto MR, Renda MC and Cottone M: Cytomegalovirus disappearance
after treatment for refractory ulcerative colitis in 2 patients
treated with infliximab and 1 patient with leukapheresis. Inflamm
Bowel Dis. 15:810–811. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
D'Ovidio V, Vernia P, Gentile G,
Capobianchi A, Marcheggiano A, Viscido A, Martino P and Caprilli R:
Cytomegalovirus infection in inflammatory bowel disease patients
undergoing anti-TNFalpha therapy. J Clin Virol. 43:180–183. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nakase H and Chiba T: TNF-alpha is an
important pathogenic factor contributing to reactivation of
cytomegalovirus in inflamed mucosa of colon in patients with
ulcerative colitis: Lesson from clinical experience. Inflamm Bowel
Dis. 16:550–551. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dignass A, Lindsay JO, Sturm A, Windsor A,
Colombel JF, Allez M, D'Haens G, D'Hoore A, Mantzaris G, Novacek G,
et al: Second European evidence-based consensus on the diagnosis
and management of ulcerative colitis part 2: Current management. J
Crohns Colitis. 6:991–1030. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Reinisch W, Reinink AR and Higgins PD:
Factors associated with poor outcomes in adults with newly
diagnosed ulcerative colitis. Clin Gastroenterol Hepatol.
13:635–642. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Monstad I, Hovde O, Solberg ICA and Moum
B: Clinical course and prognosis in ulcerative colitis: Results
from population-based and observational studies. Ann Gastroentero.
27:95–104. 2014.
|
|
19
|
Saito K, Katsuno T, Nakagawa T, Saito M,
Sazuka S, Sato T, Matsumura T, Arai M, Miyauchi H, Matsubara H and
Yokosuka O: Predictive factors of response to intravenous
ciclosporin in severe ulcerative colitis: The development of a
novel prediction formula. Aliment Pharmacol Ther. 36:744–754. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bamba S, Andoh A, Imaeda H, Ban H, Kobori
A, Mochizuki Y, Shioya M, Nishimura T, Inatomi O, Sasaki M, et al:
Prognostic factors for colectomy in refractory ulcerative colitis
treated with calcineurin inhibitors. Exp Ther Med. 4:99–104.
2012.PubMed/NCBI
|
|
21
|
Onodera T, Goseki N and Nosaki G:
Prognostic nutritional index in gastrointestinal surgery of
malnourished cancer patients. Nihon Geka Gakkai Zasshi.
85:1001–1005. 1984.(In Japanese). PubMed/NCBI
|
|
22
|
Goseki N, Okamoto A and Onodera T:
Postoperative nutritional assessment in gastric and colorectal
cancer. Nihon Geka Gakkai Zasshi. 87:853–838. 1986.(In Japanese).
PubMed/NCBI
|
|
23
|
Yagi T, Yamagishi F, Sasaki Y, Itakura M,
Fujikawa A, Kuga M and Ishimaru G: A study on cases developed
pulmonary tuberculosis after receiving gastrectomy. Kekkaku.
79:355–359. 2004.(In Japanese). PubMed/NCBI
|
|
24
|
Sagawa M, Katsube T, Konno S, Murayama M,
Yamaguchi K, Isohata N, Yoshimatsu K, Shiozawa S, Shimakawa T,
Naritaka Y and Ogawa K: The significance of Onodera's prognostic
nutritional index for the treatment of gastrointestinal cancer. Gan
To Kagaku Ryoho. 35:2253–2255. 2008.(In Japanese). PubMed/NCBI
|
|
25
|
Fukushima K, Ueno Y, Kawagishi N, Kondo Y,
Inoue J, Kakazu E, Ninomiya M, Wakui Y, Saito N, Satomi S and
Shimosegawa T: The nutritional index ‘conut’ is useful for
predicting long-term prognosis of patients with end-stage liver
diseases. Tohoku J Exp Med. 224:215–219. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kang SH, Cho KH, Park JW, Yoon KW and Do
JY: Onodera's prognostic nutritional index as a risk factor for
mortality in peritoneal dialysis patients. J Korean Med Sci.
27:1354–1358. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bamba S, Tsujikawa T, Inatomi O, Nakahara
T, Koizumi Y, Saitoh Y, Sasaki M, Fujiyama Y and Andoh A: Factors
affecting the efficacy of cyclosporin a therapy for refractory
ulcerative colitis. J Gastroenterol Hepatol. 25:494–498. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Seo M, Okada M, Yao T, Ueki M, Arima S and
Okumura M: An index of disease activity in patients with ulcerative
colitis. Am J Gastroenterol. 87:971–976. 1992.PubMed/NCBI
|
|
29
|
Kaplan GG, Seow CH, Ghosh S, Molodecky N,
Rezaie A, Moran GW, Proulx MC, Hubbard J, MacLean A, Buie D and
Panaccione R: Decreasing colectomy rates for ulcerative colitis: A
population-based time trend study. Am J Gastroenterol.
107:1879–1887. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mowat C, Cole A, Windsor A, Ahmad T,
Arnott I, Driscoll R, Mitton S, Orchard T, Rutter M, Younge L, et
al: Guidelines for the management of inflammatory bowel disease in
adults. Gut. 60:571–607. 2011. View Article : Google Scholar : PubMed/NCBI
|
